ArticleWorld journal of gastroenterology2025
Early risk stratification of post-endoscopic retrograde cholangiopancreatography pancreatitis using 4-hour serum amylase and lipase: A prospective study.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preventing Post-ERCP Pancreatitis: A Pragmatic Clinical Pathway from Periprocedural Prophylaxis to Early Postprocedural Triage.Journal of clinical medicine · 2026Review
- Harnessing early enzymatic biomarkers and cytokines for risk prediction in post-endoscopic retrograde cholangiopancreatography pancreatitis.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent diagnostic standards for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) rely on 24-hour post-ERCP amylase and lipase levels, delaying timely intervention and highlighting the need for earlier predictive biomarkers.
aimTo evaluate the utility of 4-hour post-ERCP serum amylase and lipase levels in a large cohort to establish optimal cut-off values and improve early PEP prediction.
methodsThis prospective study involved patients with naïve major papillae who underwent diagnostic or therapeutic ERCP between June 2021 and December 2024. Serum amylase and lipase levels were measured before ERCP and 4 hours and 24 hours after ERCP. The primary endpoint was to determine optimal cut-off values for 4-hour serum amylase and lipase levels for the early prediction of PEP.
resultsPEP occurred in 117 patients (6.1%). Diagnostic performance assessment of 4-hour serum amylase and lipase for predicting PEP yielded area under the curves of 0.877 and 0.893, respectively. Optimal cut-off values were 1.2 times the upper normal limit (119.5 IU/L) for amylase and 8 times the upper normal limit (488.5 IU/L) for lipase. At these thresholds, 4-hour amylase demonstrated a sensitivity of 0.846, a specificity of 0.806, and a negative predictive value of 0.988. Similarly, 4-hour lipase showed a sensitivity of 0.863, a specificity of 0.862, and a negative predictive value of 0.990. These biomarkers effectively predicted moderately severe to severe PEP in high-risk groups.
conclusionEarly measurement of 4-hour serum amylase and lipase shows strong predictive capabilities for PEP, with clinically meaningful cut-off values. These biomarkers enable timely interventions, potentially reducing PEP-related adverse events and the overall healthcare burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.